Table 2.
Suspected and confirmed STI in the assessed paratroopers and navy soldiers
| Paratroopers (n = 80) | Navy soldiers (n = 80) | |
|---|---|---|
| Proportion of suspected STI in % (n, suspected diagnoses) | 17.5% (14/80, 1x chlamydial urethritis, 1x Condylomata accuminata, 1x Molluscum contagiosium 10x not-further specified suspected STI, 1x scabies) | 20% (16/80, 5x chlamydial urethritis, 1x chlamydial urethritis + gonorrheal urethritis, 1x chlamydial urethritis + T. vaginalis infection, 4x Condylomata accuminata, 2x Condylomata accuminata + Herpes simplex virus infection, 1x gonorrheal urethritis, 1x human papillomavirus infection, 1x scabies) |
| Cases with proven STI in % (n) | 13.9% (11/79) | 11.3% (9/80) |
| Documented STI acquisition on deployment | 0% (0/6) | 10% (1/10) |
| Disease recurrence | 66.7% (2/3) | 100% (6/6) |
| Number of documented disease recurrences (x number of documentations) | 3(1x), 1 (1 x) | 3(1x), 1 (4x) |
| Localizations of STI associated lesions | 5 x genital, 1 x combined | 2x genital, 2x urethral |
| (x number of documentations) | genital + hands (scabies) | |
| Diagnostic confirmation in % (n) | 64.3% (9/14) | 64.3% (9/14) |
| Highly suggestive clinical symptoms in % (n) | 92.3% (13/14) | 73.3% (11/15) |
| Laboratory-based confirmation in % (n) | 61.5% (8/13) | 61.5% (8/13) |
| Documented therapy of sexual partners | 80% (4/5) | 83.3% (10/12 with 1 case with only non-consistent partner therapy) |
| Duration between symptoms and medical | 83.3% (5/6) | 36.4% (4/11) |
| assessment <1 month in % (n) | ||
| Duration between symptoms and medical | 0% (0/6) | 27.3% (3/11) |
| assessment <3 month in % (n) | ||
| Duration between symptoms and medical | 16.7% (1/6) | 18.2% (2/11) |
| assessment <12 month in % (n) | ||
| Pharmacological therapy performed in % (n) | 100% (12/12) | 100% (14/14) |
| Pharmacological therapy performed in line with national guidelines | 91.7% (11/12) | 85.7% (12/14) |
| Diagnostic therapy control performed in % (n) | 66.7% (8/12) | 42.9% (6/14) |
| Detection of T. vaginalis in the case of screening in % (n) | Not documented | 66.7% (2/3) |
| Detection of Chlamydia trachomatis serovar D-K in the case of screening in % (n) | 50% (3/6) | 66.7% (2/3) |
| Detection of Chlamydia trachomatis serovar L1-L3 in the case of screening in % (n) | 0% (0/6) | 0% (0/5) |
| Detection of Neisseria gonorrhoeae in the case of screening in % (n) | 0% (0/3) | 50% (2/4) |
| Serological proof of syphilis in the case of screening in % (n) | 0% (0/5) | 0% (0/4) |
| Detection of human immunodefiency virus (HIV) in the case of screening in % (n) | 0% (0/8) | 0% (0/8) |
| Detection of Mycoplasma spp. in the case of screening in % (n) | 0% (0/2) | 0% (0/1) |
| Detection of Ureaplasma spp. in the case of screening in % (n) | 0% (0/2) | 0% (0/1) |
| Detection of Klebsiella granulomatis in the case of screening in % (n) | Not documented | 0% (0/1) |
| Detection of Haemophilus ducreyi in the case of screening in % (n) | Not documented | Not documented |
| Detection of genital herpes simplex type 1 virus infections in the case of screening in % (n) | 0% (0/2) | 50% (1/2) |
| Detection of genital herpes simplex type 2 virus infections in the case of screening in % (n) | 0% (0/2) | 0% (0/1) |
| Detection of human papillomavirus in the case of screening in % (n) | 80% (4/5) | 85.7% (6/7) |
| Detection of hepatitis B virus in the case of screening in % (n) | 0% (0/73) | 0% (0/49) |
| Detection of hepatitis C virus in the case of screening in % (n) | 0% (0/12) | 0% (0/9) |
| Detection of Molluscum contagiosum virus in the case of screening in % (n) | Not documented | 100% (1/1) |
| Detection of Sarcoptes scabiei in the case of screening in % (n) | 100% (3/3) | 50% (1/2) |
| Detection of Phthirus pubis in the case of screening in % (n) | Not documented | Not documented |
| Detection of G. vaginalis in the case of screening in % (n) | Not documented | 100% (1/1) |